Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BioInformant Worldwide LLC | PRODUCT CODE: 1177298

Cover Image

PUBLISHER: BioInformant Worldwide LLC | PRODUCT CODE: 1177298

Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2023

PUBLISHED:
PAGES: 321 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4497
PDF (Site License)
USD 4997
PDF (Global License)
USD 5497

Add to Cart

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once infused into the patient, these CARs enable the T-cells to recognize and attach to an antigen on the cancer cell, leading to its destruction.

Scientific progress within the field of cancer immunotherapy has led to seven CAR-T cell therapy approvals, including:

  • 1. Kymriah (tisagenlecleucel)
  • 2. Yescarta (axicabtagene ciloleucel)
  • 3. Tecartus (brexucabtagene autoleucel)
  • 4. Breyanzi (lisocabtagene maraleucel)
  • 5. Abecma (idecabtagene vicleucel)
  • 6. Relma-cel (Relmacabtagene)
  • 7. Carvykti (Ciltacabtagene autoleucel)

While Relma-cel has been approved by NMPA in China, all the other six therapies have been approved in the U.S. by the FDA.

These historic approvals demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm. This has driven CAR-T funding to staggering new heights. At first the trend was subtle, but the tide has swelled as CAR-T start-ups have been richly funded by investors eager to get into this expanding area of regenerative medicine. In total, there has been an astonishing $100 billion of market capitalization from CAR-T companies in recent years.

Financing rounds by CAR-T companies have approached $4 billion, while CAR-T industry partnerships have contributed an astounding $2 billion. M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead's acquisition of Kite Pharma for $11.9 billion also made waves, as did other transactions, such as Astellas Pharma's acquisition of Xyphos Biosciences and its CAR-T technology for $665 million. The billion-dollar CAR-T cell therapy market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

This 321-page market report reveals:

  • Global CAR-T Cell Therapy Market Size, with Segmentation by Product, Geography, and Indication
  • Future Market Size Forecasts by Segment through 2030
  • Detailed Coverage of the Approved CAR-T Products, including Regulatory Approvals, Pricing, Reimbursement, and Degree of Market Penetration
  • Clinical Trial Activity by Type, Geography, Phase, and Sponsor
  • Comprehensive CAR-T Patent Analysis, including Top Inventors, Patent Holders, Patent Types, Geographies, and Most Cited Patents
  • CAR-T Industry Mergers and Acquisitions, IPOs, and Financing Events
  • Strategic Partnerships, Alliances, and Co-commercialization Agreements within the CAR-T sector
  • Market Trends, Future Directions, and Emerging Opportunities
  • Profiles of Leading CAR-T Competitors Composing the Global Marketplace
  • And Much More

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT

  • 2.1. CAR-T Cell
  • 2.2. Evolution of CAR-T Cell Development
    • 2.2.1. The CAR-T Cell Family
      • 2.2.1.1. First Generation CARs
      • 2.2.1.2. Second Generation CARs
      • 2.2.1.3. Third Generation CARs
      • 2.2.1.4. Fourth Generation CARs
      • 2.2.1.5. Fifth Generation CARs
  • 2.3. Antigens Present on Hematological Malignant Cells
  • 2.4. Tools for Inserting Receptor Genes into T Cells
  • 2.5. Transforming T Cells into CAR-T Cells
  • 2.6. The Seven CAR-T Therapies Available in the Market: A Brief Overview
  • 2.7. Toxicities Associated with CAR-T Treatment
  • 2.8. Strategies for the Future of CAR-T Therapies
    • 2.8.1. Switchable CARs (sCARs)
    • 2.8.2. Suicide Genes to Destroy CAR-T Cells In Vivo
    • 2.8.3. Transient Transfection
    • 2.8.4. Affinity Tuned CARs
    • 2.8.5. Armored CARs
    • 2.8.6. Shift from Liquid Cancers to Solid Tumors
    • 2.8.7. Focus on Shortening Hospital Stay
    • 2.8.8. Focus on Discovering New Antigens
    • 2.8.9. Shifting from Autologous to Allogeneic CAR-T Therapies
    • 2.8.10. CAR-T for the Masses
    • 2.8.11. New In Vivo CAR-T Approach
    • 2.8.12. Combination with mRNA Vaccine
    • 2.8.13. Combination with Oncolytic Virus
  • 2.9. Direct Competion between Autologous CAR-T Therapies

3. CAR-T CELL THERAPY: PRODUCT DEVELOPMENT

  • 3.1. History of Development of CAR-T Cells
  • 3.2. Top Ten Milestones Crossed by CAR-T Therapy
    • 3.2.1. First Pediatric Patient to Receive CAR-T Therapy
    • 3.2.2. CAR-T Granted Breakthrough Therapy Designation
    • 3.2.3. The Beginning of CAR-T Development to Combat Solid Cancers
    • 3.2.4. First CRISPR CAR-T Built
    • 3.2.5. The First Two CAR-T Approvals
    • 3.2.6. EMA's Approval for Kymriah and Yescarta
    • 3.2.7. Approval of Tecartus, Breyanzi and Abecma
    • 3.2.8. NMPA Approval of Relma-cel (Carteyva)
    • 3.2.9. Approval of Carvykti
  • 3.3. Current Status of CAR-T Therapy Products
    • 3.3.1. Kymriah (Tisagenlecleucel)
      • 3.3.1.1. Kymriah's Mechanism of Action
      • 3.3.1.2. Clinical Trials on Kymriah
    • 3.3.2. Yescarta (Axicabtagene ciloleucel)
      • 3.3.2.1. Mechanism of Action
      • 3.3.2.2. Yeskarta on Clinical Trials
    • 3.3.3. Tecartus (Brexucabtagene autoleucel)
      • 3.3.3.1. Tecartus Approvals
      • 3.3.3.2. Mechanism of Action
      • 3.3.3.3. Clinical Trials on Tecartus
    • 3.3.4. Breyanzi (Lisocabtagene maraleucel)
    • 3.3.5. Abecma (Idecabtagene vicleucel)
      • 3.3.5.1. Regulatory Approvals for Abecma
      • 3.3.5.2. Mechanism of Action
      • 3.3.5.3. Clinical Trials on Abecma
    • 3.3.6. Relma-Cel (Relmacabtagene autoleucel)
    • 3.3.7. Carvykti (Ciltacabtagene autoleucel)
      • 3.3.7.1. Regulatory Approvals for Carvykti
      • 3.3.7.2. Mechanism of Action
      • 3.3.7.3. Clinical Trials on Carvykti
  • 3.4. Other Promising CAR-T Product Candidates
    • 3.4.1. ALLO-501
    • 3.4.2. CTX-110
    • 3.4.3. UCART19
    • 3.4.4. AUT01
    • 3.4.5. JCARH125
    • 3.4.6. PBCAR20A
    • 3.4.7. UCART123
    • 3.4.8. PRGN-3006
    • 3.4.9. UCART22
    • 3.4.10. UCARTCS1
  • 3.5. Transformative Potential of CAR-T Therapy
  • 3.6. Cancer Population Addressed by CAR-T Therapy
  • 3.7. Advantages of CAR-T Cell Therapy
  • 3.8. Disadvantages of CAR-T Therapy

4. SCALABLE MANUFACTURING OF CAR-T CELLS

  • 4.1. The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • 4.2. The Evolution of CAR-T Cell Manufacturing Platforms
    • 4.2.1. Open vs. Closed Systems
    • 4.2.2. Manual Processing vs. Automation
    • 4.2.3. Autologous vs. Allogeneic Manufacturing
  • 4.4. Operating Expenses in Autologous CAR-T Manufacturing
  • 4.5. Operating Expenses in Allogeneic CAR-T Manufacturing

5. CAR-T TARGET ANTIGENS

  • 5.1. CAR-T Target Antigens on Hematalogical Malignancies
  • 5.2. CAR-T Target Antigens on Solid Tumors
  • 5.3. Common Antigens Targeted by CAR-T Cells in Clinical Trials
    • 5.3.1. Cluster of Differentiation 19 (CD19)
    • 5.3.2. Mesothelin
    • 5.3.3. B-Cell Maturation Agent (BCMA)
    • 5.3.4. GD2
    • 5.3.5. Glypican-3 (GPC3)
    • 5.3.6. Cluster Differentiation-22 (CD22)

6. CAR-T PATENT LANDSCAPE

  • 6.1. Geographical Origin of CAR-T Patent Applications
  • 6.2. Top Ten CAR-T Patent Jurisdictions
  • 6.3. Affiliations of CAR-T Patent Applicants
  • 6.4. Top 20 Companies in CAR-T Patent Landscape
  • 6.5. Top 20 Research Centers in CAR-T Patent Landscape
  • 6.6. Top Ten CAR-T Inventors
  • 6.7. Top Five CAR-T Patents with Most Family Members
  • 6.8. Top Five CAR-T Patents with Most Inventors in Co-Authorship
  • 6.9. Top Five Patents with Most Co-Applicants
  • 6.10. Top 5 CAR-T Patents with Most Co-Applicants

7. CAR-T CLINICAL TRIAL LANDSCAPE

  • 7.1. Most Addressed Indications in Clinical Trials
  • 7.2. Current Focus of Ongoing Clinical Trials
  • 7.3. Countries with Most Clinical Trials
  • 7.4. Phase of Clinical Trial Studies
  • 7.5. CAR-T Clinical Trials for Hematalogical Malignancies
  • 7.6. Simultaneous Targets by One CAR-T
  • 7.7. CAR-T Generations Used in Clinical Trials
  • 7.8. CAR-T Clinical Trials Focusing on Solid Tumors
  • 7.9. CAR-T Targeted Biomarkers in Clinical Trials
  • 7.10. CAR-T Targeted Biomarkers in the U.S. Clinical Trials
  • 7.11. CAR-T Targeted Biomarkers in Chinese Clinical Trials
  • 7.12. CAR-T Targeted Indications in the U.S. Clinical Trials
  • 7.13. Indications Addressed by CAR-T Clinical Trials in China
  • 7.14. Hematological Malignancies v.s. Solid Cancers in CAR-T Clinical Trials
  • 7.15. CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
  • 7.16. CAR-T Clinical Trial Sponsor Companies & Institutions in China
  • 7.17. CAR-T Clinical Trial Sponsor Companies & Institutions in other Countries
  • 7.18. Improved CAR-T Constructs in Clinical Trials
    • 7.18.1. CAR-T with PD1Fc
    • 7.18.2. CAR-T with Truncated with EGFR (EGFRt)
    • 7.18.3. CAR-T with IL7 and CCL19
    • 7.18.4. CAR-T with PD1/CD28 Switch Receptor
    • 7.18.5. CAR-T with PD1 shRNA Expressing Cassette
    • 7.18.6. CAR-T with CTLA-4/PD-1 Antibody
    • 7.18.7. CAR-T with PD-1 Antibodies
  • 7.19. Distribution of CAR-T Trials by Type of SeFv Used
  • 7.20. Distribution of CAR-T Clinical Trials by Type of Vectors Used

8. PUBLISHED CAR-T SCIENTIFIC PAPERS IN PUBMED.GOV & NIH FUNDING

  • 8.1. PubMed.gov Published Papers on the Five Generation of CARs
  • 8.2. PubMed.gov Papers Published on Autologous and Allogeneic CAR-Ts
  • 8.3. Published CAR-T PubMed Papers on Solid & Liquid Cancers
  • 8.4. NIH Funding for CAR-T Research in 2022

9. DEALS IN CAR-T THERAPY SPACE

  • 9.1. Most Recent CAR-T Deals
    • 9.1.1. Autolus Therapeutics/Bristol Myers Squibb
    • 9.1.2. ArsenalBio/Genentech
    • 9.1.3. Chugai Pharmaceutical/Noile Immune Biotech
    • 9.1.4. Roche/Poseida Therapeutics
    • 9.1.5. Oxford Biomedica/Undisclosed U.S. Company
    • 9.1.6. Immatics/Bristol Myers Squibb
    • 9.1.7. Galapagos/CellPoint/AboundBio
    • 9.1.8. Coeptis/University of Pittsburgh
    • 9.1.9. Pregene/CellPont
    • 9.1.10. Intellia/Kyverna
  • 9.2. Funding for CAR-T Therapy in H1 2022
    • 9.2.1. Neukio Bio
    • 9.2.2. Arsenal Biosciences
    • 9.2.3. Eyestem
    • 9.2.4. Legend Biotech
    • 9.2.5. Immuneel Therapeutics
    • 9.2.6. Tessa Therapeutics
    • 9.2.7. Elicera Therapeutics
    • 9.2.8. Inceptor Bio
    • 9.2.9. AvenCell Therapeutics
    • 9.2.10. Ucello Theraputics
    • 9.2.11. Kyverna Therapeutics

10. REIMBURSEMENT FOR CAR-T THERAPIES

  • 10.1. Potential Barriers to CAR-T Treatments
    • 10.1.1. Patient Barriers
    • 10.1.2. Limited Number of Treatment Centers
    • 10.1.3. Travel, Lodging & Meal Expenses
    • 10.1.4. Utilization Management Policies
    • 10.1.5. Out-of-Pocket Costs
    • 10.1.6. Geography
    • 10.1.7. Logistics of Follow-Up
    • 10.1.8. Reimbursement Uncertainty
  • 10.2. Manufacturer Challenges
    • 10.2.1. Lingering Manufacturing Issues
    • 10.2.2. Difficulties with Scaling Up
  • 10.3. CAR-T Reimbursement Updated for FY 2023 IPPS Final Rule
    • 10.3.1. Payment Changes for CAR-T Cases
    • 10.3.2. High-Cost Outlier Payments
  • 10.4. Use of 2021 Data to Establish Payment
    • 10.4.1. Adjustment for Clinical Trial Cases
    • 10.4.2. Product NTAP Decisions
  • 10.5. Reimbursement for CAR-T Therapy in Europe
    • 10.5.1. Cost Components of Pre- and Post-CAR-T Cell Therapy
    • 10.5.2. Average Total Costs Pre- and Post CAR-T Cell Administration in E.U.
  • 10.6. Outcomes-Based Reimbursement for CAR-T Therapies in Europe
    • 10.6.1. France
    • 10.6.2. Germany
    • 10.6.3. Italy
    • 10.6.4. Spain
    • 10.6.5. Reimbursement for CAR-T Therapies in U.K.
  • 10.7. CAR-T Cell Treated Patients Registered in EBMT Registry

11. BLOOD CANCERS: INCDENCE AND AVAILABLE TREATMENTS

  • 11.1. Lymphoma
    • 11.1.1. Hodgkin Lymphoma (HL)
    • 11.1.2. Non-Hodgkin Lymphoma (NHL)
    • 11.1.3. Difuse Large B Cell Lymphoma (DLBCL)
    • 11.1.4. Follicular Lymphoma (FL)
  • 11.2. Leukemia
    • 11.2.1. Types of Leukemia
      • 11.2.1.1. Acute Myeloid Leukemia (AML)
      • 11.2.1.2. Acute Lymphoblastic Leukemia (ALL)
      • 11.2.1.3. Chronic Myeloid Leukemia (CML)
      • 11.2.1.4. Chronic Lymphocytic Leukemia (CLL)
      • 11.2.1.5. Multiple Myeloma (MM)
  • 11.3. Treatment Options for Blood Cancers
    • 11.3.1. Chemotherapy
    • 11.3.2. Radiation Therapy
    • 11.3.3. Targeted Therapy
    • 11.3.4. Stem Cell Transplantation
    • 11.3.5. Immunotherapy
      • 11.3.5.1. Monoclonal Antibodies (mAbs)
    • 11.3.6. Adoptive Cell Transfer Therapy/T Cell Transfer Therapy
  • 11.4. The Staggering Cost of Cancer Therapies

12. MARKET ANALYSIS

  • 12.1. Global Market for CAR-T Cell Therapy by Product
  • 12.2. Global Market for CAR-T Therapy by Geography
  • 12.3. Global Market for CAR-T Therapy by Indication

13. BARRIERS & STRATEGIES FOR SUCCESS IN CAR-T 2.0 MARKET PLACE

  • 13.1. Barriers to CAR-T 2.0 Commercial Success
  • 13.2. Capacity Constraints
  • 13.3. Competition among Manufacturers
  • 13.4. Competition from other Treatments
  • 13.5. Market Development Strategies for CAR-T 2.0
    • 13.5.1. Effective Physician Education
    • 13.5.2. Logistical Excellence
    • 13.5.3. Evidence Generation

14. CAR-T COMPANIES: AN OVERVIEW

  • 14.1. Abintus Bio, Inc.
  • 14.2. Adicet Bio
    • 14.2.1. Gamma Delta T Cells
    • 14.2.2. Proprietary Cell Platform Process
    • 14.2.3. Pipeline
  • 14.3. AffyImmune Therapeutics, Inc.
    • 14.3.1. Affinity-Tuned CARs
    • 14.3.2. Real-Time CAR-T Cell Monitoring
  • 14.4. Alaunos Therapeutics, Inc.
  • 14.5. Aleta BioTherapeutics
    • 14.5.1. Aleta's CAR-T Engager Pipeline
  • 14.6. Allogene Therapeutics
    • 14.6.1. AlloCAR-T
  • 14.7. Anixa Biosciences, Inc.
  • 14.8. Appia Bio
  • 14.9. Arbele Ltd.
    • 14.9.1. AI-CAR-T/NK Cell Platform
  • 14.10. Arcellx
    • 14.10.1. D-Domain Technology
    • 14.10.2. ddCAR
    • 14.10.3. ARC-SparX
  • 14.11. Artiva Biotherapeutics
    • 14.11.1. Artiva's AlloNK Platform
    • 14.11.2. Artiva's CAR-NK Platform
  • 14.12. Atara Biotherapeutics
    • 14.12.1. Technology
    • 14.12.2. Atara's Robust Pipeline
  • 14.13. Aurora BioPharma
  • 14.14. Autolus Therapeutics plc
    • 14.14.1. Technology
    • 14.14.2. CAR-T Cell Production
    • 14.14.3. Manufacturing
    • 14.14.4. Autolus' Therapies in Development
    • 14.14.5. obe-cel
  • 14.15. AvenCell Europe GmbH
    • 14.15.1. AvenCell's Proprietary Platforms
    • 14.15.2. UniCAR
    • 14.15.3. RevCAR
    • 14.15.4. TCE
    • 14.15.5. AvenCell's Clinical and Preclinical Pipeline
  • 14.16. Aavocyte, Inc.
    • 14.16.1. AAVOT Technology
    • 14.16.2. Indications for AAVOT Therapy
  • 14.17. Beam Therapeutics, Inc.
    • 14.17.1. Base Editing Technology
  • 14.18. Bellicum Pharmaceuticals
    • 14.18.1. GoCAR Technology
    • 14.18.2. CaspaCIDe Safety Switch
  • 14.19. BioNTech
    • 14.19.1. BioNTech's Engineered Cell Therapies
    • 14.9.2. BNT211
    • 14.19.3. BNT212
  • 14.20. Biosceptre
    • 14.20.1. nfP2X7
    • 14.20.2. Biosceptre's Product Pipeline
  • 14.21. bluebird bio
    • 14.21.1. CAR-T Collaborations
    • 14.21.2. Collaboration with Celgene
    • 14.21.3. Collaboration with Bristol Myers Squibb
    • 14.21.4. Collaboration with TC BioPharm
    • 14.21.5. Collaboration with Inhibrx
    • 14.21.6. Collaboration with PsiOxus
  • 14.22. Bristol Myers Squibb/Celgene Corp.
    • 14.22.1. Products
      • 14.22.1.1. ABECMA (idecabtagene vicleucel)
      • 14.22.1.2. Breyanzi (lisocabtagene maraleucel)
  • 14.23. Cabaletta Bio
    • 14.23.1. CAAR Technology
  • 14.24. Carina Biotech
  • 14.25. CARsgen Therapeutics
  • 14.26. Cartesian Therapeutics
    • TABLE 14.19: Cartesian's Growing Product Pipeline
  • 14.27. CARTherics Pty Ltd.
    • 14.27.1. Technology
  • 14.28. Cellectis
    • 14.28.1. Product Candidates
    • TABLE 14.20: Cellectis' Products in Development
  • 14.29. CellPoint BV
  • 14.30. Celularity, Inc.
    • 14.30.1. P CAR-T
  • 14.31. Celyad Oncology
    • 14.31.1. Technologies
    • 14.31.2. All-In-One Vector Approach
    • 14.31.3. Pipeline
  • 14.32. Century Therapeutics, Inc.
    • 14.32.1. Century's Approach
    • 14.32.2. Gene Editing Technology
    • 14.32.3. Proprietary Allo-Evasion Technology
    • 14.32.4. CAR and Protein Engineering
    • 14.32.5. Common Engineered iPSC Progenitors
    • 14.32.6. Streamlined Manufacturing
    • 14.32.7. Century's Pipeline Overview
  • 14.33. Clade Therapeutics
  • 14.34. Coeptis Therapeutics, Inc.
    • 14.34.1. SNAP CAR-T
  • 14.35. Creative Biolabs
    • 14.35.1. CAR-T Therapy Development
    • 14.35.2. Biomarker Identification and Selection
    • 14.35.3. scFv Generation
    • 14.35.4. CAR-T Gene Packaging & Delivery
    • 14.35.5. Replication-Competent Virus Testing Service
    • 14.35.6. CAR Cell In Vitro Assay Service
    • 14.35.7. CAR-T Preclinical In Vivo Assay
    • 14.35.8. IND Development for CAR-T Cell Therapy
    • 14.35.9. GMP Production for CAR-T Products
    • 14.35.10. CAR-T Clinical Trials
  • 14.36. CRISPR Therapeutics
    • 14.36.1. CRISPR/Cas9 Immuno-Oncology Cell Therapy
    • 14.36.2. CRISPR/Cas9 Allogeneic CAR-T Design
  • 14.37. Curocell, Inc.
    • 17.37.1. OVIS Technology
  • 17.38. CytoSeek
    • 14.38.1. Technology
    • 14.38.2. Pipeline
  • 14.39. Cytovia Therapeutics
    • 14.39.1. Technology
  • 14.40. DiaCarta
    • 14.40.1. Personalized CAR-T Immunotherapy Platform
  • 14.41. Elicera Therapeutics AB
    • 14.41.1. iTANK CAR-T Technology
    • 14.41.2. Elicera's Product Pipeline
  • 14.42. Eureka Therapeutics, Inc.
    • 14.42.1. Technology
      • 14.42.1.1. E-ALPHA Phage Display Platform
      • 14.42.1.2. ARTEMIS Cell Receptor Platform
    • 14.42.2. Eureka's Product Pipeline
  • 14.43. EXUMA Biotech Corp.
    • 14.43.1. TMR CAR-T Technology
  • 14.44. Fate Therapeutics, Inc.
  • 14.45. Gilead Sciences, Inc.
    • 14.45.1. CAR-T Products
      • 14.45.1.1. TECARTUS (Brexucabtagene autoleucel)
      • 14.45.1.2. Yescarta (Axicabtagene ciloleucel)
    • 14.45.2. CAR-T Programs
  • 14.46. Gracell Biotechnologies
    • 14.46.1. FasTCAR
    • 14.46.2. TruUCAR
    • 14.46.3. SMART CART
    • 14.46.4. Gracell's Clinical Pipeline
  • 14.47. IASO Biotherapeutics
    • 14.47.1. Technology Platforms
      • 14.47.1.1. Fully Human Antibody Discovery Platform (IMARS)
      • 14.47.1.2. High-Throughput Screening Platform for CAR-T Candidates
      • 14.47.1.3. Universal CAR-T Technology Platform
      • 14.47.1.4. Manufacturing Technology Platform
    • 14.47.2. IASO's Diverse Product Pipeline
  • 14.48. iCell Gene Therapeutics
    • 14.48.1. CARvac Platform
    • 14.48.2. T-Cell Targeted CARs
    • 14.48.3. Non-Gene Edited Universal CARs
    • 14.48.4. C-TPS1
    • 14.48.5. Compound CARs
    • 14.48.5. Pipeline
  • 14.49. ImmPACT Bio
    • 14.49.1. Technologies
      • 14.49.1.1. Dual-Targeted CAR-T Cell Therapy
      • 14.49.1.2. ICAR Dual Targeting Technology
      • 14.49.1.3. TGF-B CARS Targeting TME
  • 14.50. Immuneel Therapeutics, Pvt. Ltd.
  • 14.51. Inceptor Bio
    • 14.51.1. Inceptor's Technology Platforms
  • 14.52. Interius BioTherapeutics
    • 14.52.1. Core Technology
  • 14.53. Janssen Biotech, Inc.
    • 14.53.1. JNJ-4528
  • 14.54. JW Therapeutics
    • 14.54.1. Relma-cel (JWCAR029)
  • 14.55. Kite Pharma (Gilead)
    • 14.55.1. Kite's Technology
    • 14.55.2. Kite's Marketed Therapies
      • 14.55.2.1. Yescarta (Axicabtagene ciloleucel)
      • 14.55.2.2. Tecartus (Brexucabtagene autoleucel)
    • 14.55.3. Kite's Pipeline Cancer Therapies
  • 14.56. Kuur Therapeutics
    • 14.56.1. Kuur's Product Candidates
  • 14.57. Kyverna Therapeutics
    • 14.57.1. CAR-T Cells
      • 14.57.1.1. SynNotch CAR-T Cells
      • 14.57.1.2. SynReg T Cells
  • 14.58. Legend Biotech
    • 14.58.1. LCAR-B38M/JNJ-4528
  • 14.59. Leucid Bio
    • 14.59.1. Leucid's Science
    • 14.59.2. Leucid's Product Pipeline
  • 14.60. Luminary Therapeutics, Inc.
    • 14.60.1. BAFF CAR-T
    • 14.60.2. Universal Receptor
    • 14.60.3. Luminary Therapeutics' Pipeline
  • 14.61. Lyell Immunopharma, Inc.
    • 14.61.1. Technologies
      • 14.61.1.1. Gen-R Technology
      • 14.61.1.2. Epi-R Technology
  • 14.62. MaxCyte, Inc.
    • 14.62.1. ExPERT Technology Platform
      • 14.62.1.1. ATx
      • 14.62.1.2. GTx
      • 14.62.1.3. STx
      • 14.62.1.4. VLx
  • 14.63. Minerva Biotechnologies Corporation
    • 14.63.1. Autologous huMNC2-CAR44
  • 14.64. Mnemo Therapeutics
    • 14.64.1. Mnemo's Approach
      • 14.64.1.1. Mnemo's 1XX CAR
  • 14.65. Mustang Bio
  • 14.66. Neukio Biotherapeutics
    • 14.66.1. iPSC-CAR-NK Technology
  • 14.67. NKarta, Inc.
    • 14.67.1. Technology
    • 14.67.2. NKarta's Pipeline
  • 14.68. Noile-Immune Biotech
    • 14.68.1. PRIME Technology
  • 14.69. Novartis AG
    • 14.69.1. The Pioneers of CAR-T Cell & Gene Therapy
    • 14.69.2. Approval of Kymriah (tisagenlecleucel)
  • 14.70. Oncternal Therapeutics
    • 14.70.1. Oncternal's Product Pipeline
  • 14.71. Orna Therapeutics
    • 14.71.1. oRNA Circular RNA
    • 14.71.2. oRNA's Pipeline Products
  • 14.72. Oxford Biomedica plc
    • 14.72.1. LentiVector Platform
    • 14.72.2. LentiStable Platform
    • 14.72.3. Adeno-Associated Virus (AAV) Platform
    • 14.72.4. TRiP System
  • 14.73. PeproMene Bio, Inc.
    • 14.73.1. BAFFR CAR-T Cells
    • 14.73.2. Bispecific T Cell Engager (BiTE)
    • 14.73.3. CAR NK Cells
  • 14.74. Poseida Therapeutics, Inc.
    • 14.74.1. Platforms
      • 14.74.1.1. piggyBac
      • 14.74.1.2. Cas-CLOVER
      • 14.74.1.3. Gene Delivery
      • 14.74.1.4. TSCM Cells
    • 14.74.2. Pipeline Products
      • 14.74.2.1. P-BCMA-ALL01
      • 14.74.2.2. P-MUC1C-ALL01
      • 14.74.2.3. P-PSMA-ALL01
      • 14.74.2.4. Dual CAR Allogeneic Programs
      • 14.74.2.5. P-PSMA-101
  • 14.75. Precigen, Inc.
    • 14.75.1. Therapeutic Platforms
      • 14.75.1.1. UltraCAR-T
      • 14.75.1.2. AdenoVerse Immunotherapy
      • 14.75.1.3. ActoBiotics
      • 14.75.1.4. Multifunctional Therapeutics
    • 14.75.2. Technology Platforms
      • 14.75.2.1. UltraVector
      • 14.75.2.2. Sleeping Beauty System
      • 14.75.2.3. AdenoVerse
      • 14.75.2.4. UltraPorator
      • 14.75.2.5. RheoSwitch
    • 14.75.3. Precigen's Pipeline
  • 14.76. Precision Biosciences
    • 14.76.1. ARCUS Genome Editing
    • 14.76.2. Precision's CAR-T Immunotherapy Pipeline
  • 14.77. Prescient Therapeutics
    • 14.77.1. Technology
      • 14.77.1.1. OmniCAR
      • 14.77.1.2. CellPryme-M
      • 14.77.1.3. PTX-100
      • 14.77.1.4. PTX-200
  • 14.78. ProMab Biotechnologies, Inc.
    • 14.78.1. Products
    • 14.78.2. Services
      • 14.78.2.1. Cell Line Engineering Services
      • 14.78.2.2. Custom CAR-T Cell Development
      • 14.78.2.3. Custom CAR-NK Cell Development
      • 14.78.2.4. Custom CAR-Macrophage Cell Development
      • 14.78.2.5. Custom Gamma Delta T Cell Development
    • 14.78.3. Lentivirus Production
    • 14.78.4. mRNA-Lipid Nanoparticle Gene Delivery
    • 14.78.5. Cancer Stem Cell Line Services
  • 14.79. Quell Therapeutics, Ltd.
    • 14.79.1. Quell's Platform
  • 14.80. Sorrento Therapeutics, Inc.
    • 14.80.1. DAR-T (Dimeric Antigen Receptor T Cell)
  • 14.81. SOTIO Biotech, A.S.
    • 14.81.1. SOTIO's Pipeline
  • 14.82. Syngene International, Ltd.
    • 14.82.1. CAR-T Services
  • 14.83. Synthekine
    • 14.83.1. STK-009 + SYNCAR-001
  • 14.84. TC BioPharm
    • 14.84.1. Gamma Delta T Cells
    • 14.84.2. Cell Banks
    • 14.84.3. Co-Stim CAR-T
    • 14.84.4. TC BioPharm's Product Pipeline
    • 14.84.5. Omnlmmune
    • 14.84.6. CAR-T Programs
  • 14.85. T-CURX
    • 14.85.1. CARAMBA Project
    • 14.85.2. imSAVAR Project
  • 14.86. Tessa Therapeutics, Ltd.
  • 14.87. Tmunity Therapeutics
    • 14.87.1. Technology
    • 14.87.2. Pipeline
  • 14.88. Umoja Biopharma
    • 14.88.1. Umoja's Core Technology Platforms
      • 14.88.1.1. VivoVec in vivo Gene Delivery
      • 14.88.1.2. RACR/CAR in vivo Cell Programming
      • 14.88.1.3. TumorTag (Universal CAR Tumor Targeting)
  • 14.89. Vor Biopharma
    • 14.89.1. Vor Biopharma's Ap[proach
    • 14.89.2. Vor's Platform
    • 14.89.3. Vor's Pipeline
  • 14.90. Wugen
  • 14.91. WuXi Advanced Therapies
    • 14.91.1. Closed-Process CAR-T Platform
  • 14.92. Xenetic Biosciences
    • 14.92.1. The DNase Platform Technology
    • 14.92.2. XCART Personalized CAR-T Platform Technology
    • 14.92.3. PolyXen PSA Technology Platform
  • 14.93. Xyphos Biosciences, Inc.
    • 14.93.1. ACCEL & UDC Technology
    • 14.93.2. convertibleCAR
    • 14.93.3. Univeral Donor Cells

INDEX OF FIGURES

  • FIGURE 2.1: The Basic Structure of a T cell
  • FIGURE 2.2: Binding of a T cell onto an Infected Cell
  • FIGURE 2.3: Components of a CAR-T Cell
  • FIGURE 2.4: The Three Domains of a CAR
  • FIGURE 2.5: The First Generation CARs
  • FIGURE 2.6: Second Generation CARs
  • FIGURE 2.7: Third Generation CARs
  • FIGURE 2.8: Fourth Generation CARs
  • FIGURE 2.9: Fifth Generation CARs
  • FIGURE 2.10: Antigens Present on Normal & Cancer Cells
  • FIGURE 2.11: The Process of CAR-T Manufacturing
  • FIGURE 2.12: Preparation & Administration of CAR-T Therapy
  • FIGURE 3.1: The Five Generations of CARs
  • FIGURE 3.2: A Package of Kymriah
  • FIGURE 3.3: Yescarta in a Blood Bag
  • FIGURE 3.4: Tecartus in a Blood Bag
  • FIGURE 3.5: Abecma in a Blood Bag
  • FIGURE 3.6: Relma-cel in a Blood Bag
  • FIGURE 3.7: Carvykti in a Blood Bag
  • FIGURE 4.1: The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • FIGURE 4.2: G-Rex Bioreactors
  • FIGURE 4.3: CliniMACS Prodigy
  • FIGURE 4.4: Scaling Up of Allogeneic CAR-T Cells
  • FIGURE 4.5: Operating Expenses in Autologous CAR-T Manufacturing
  • FIGURE 4.6: Operating Expenses in Allogeneic CAR-T Manufacturing
  • FIGURE 5.1: CAR-T Global Distribution in Clinical Trials
  • FIGURE 6.1: CAR-T Patent Publications
  • FIGURE 6.2: Granted CAR-T Patents
  • FIGURE 6.3: Geographical Origin of CAR-T Patent Applications
  • FIGURE 6.4: Top Ten CAR-T Patent Jurisdictions
  • FIGURE 6.5: Affiliations of CAR-T Patent Applicants
  • FIGURE 7.1: Percent Share of CAR-T Clinical Trials by Phase
  • FIGURE 7.2: Percent Share of Hematological Malignancy Types in CAR-T Clinical Trials
  • FIGURE 7.3: Simultaneous Targets by One CAR-T
  • FIGURE 7.4: CAR-T Generations Used in Clinical Trials
  • FIGURE 7.5: % Share of Ten Major Solid Tumor Indications in CAR-T Clinical Trials
  • FIGURE 7.6: Hematological Malignancies v.s. Solid Cancers in CAR-T Clinical Trials
  • FIGURE 7.7: Distribution of CAR-T Clinical Trials by ScFv Used
  • FIGURE 7.8: Distribution of CAR-T Clinical Trials by Type of Vectors Used
  • FIGURE 8.1: Number of Published CAR-T Papers in PubMed.gov
  • FIGURE 8.2: Published PubMed Papers on the Five Generations of CAR-Ts
  • FIGURE 8.3: Published PubMed Papers, Autologous v.s Allogeneic CAR-Ts
  • FIGURE 8.4: Published CAR-T PubMed Papers on Solid & Liquid Cancers
  • FIGURE 10.1: CAR-T Cell Treated Patients Registered in EBMT Registry
  • FIGURE 11.1: Global Incidence of Blood Cancers & Death in 2020
  • FIGURE 11.2: Percent Distribution of New Leukemia Cases in the U.S. by Type
  • FIGURE 12.1: Estimated Global Market for CAR-T Therapy by Product, 2022-2030
  • FIGURE 12.2: Global Market for CAR-T by Geography, 2021-2030
  • FIGURE 12.3: Global Market for CAR-T Therapies by Indication, 2021-2030
  • FIGURE 14.1: Proprietary Cell Platform Process
  • FIGURE 14.2: Atara's Differentiated Approach to Allogeneic Cell Therapy
  • FIGURE 14.3: Schematic of P CAR-T with TCR-KO
  • FIGURE 14.4: All-In-One Vector Approach
  • FIGURE 14.5: Century's Approach in Developing Drug Product
  • FIGURE 14.6: Century's Precision Gene Editing Technology
  • FIGURE 14.7: Century's Allo-Evasion Technology
  • FIGURE 14.8: Century's CAR Engineering
  • FIGURE 14.9: Century's Common Engineered iPSC Progenitors
  • FIGURE 14.10: Difference between Donor-Derived and iPSC-Derived Cell Expansion
  • FIGURE 14.11: OVIS Technology
  • FIGURE 14.12: FasTCAR vs. Conventional CAR-T Manufacturing Process
  • FIGURE 14.13: Schematic of CD19/CD20 CAR-T Technology
  • FIGURE 14.14: Schematic of SynNotch CAR-T Cells Recognizing Target Cells
  • FIGURE 14.15: Schematic of Reprogrammed SynReg T Cells Targeting Disease Tissues
  • FIGURE 14.16: Schematic of BAFF CAR-T's Action
  • FIGURE 14.17: ATx
  • FIGURE 14.18: GTx
  • FIGURE 14.19: STx
  • FIGURE 14.20: MaxCyte VLx
  • FIGURE 14.21: NKarta's Engineered CAR-NK Cell
  • FIGURE 14.22: Mechanism of Action of BAFFR CAR-T Cells
  • FIGURE 14.23: Mechanism of Action of BAFF-R BiTE
  • FIGURE 14.24: PeproMene's CAR NK Cells
  • FIGURE 14.25: UltraCAR-T Cell
  • FIGURE 14.26: WuXi's Closed-Process CAR-T Platform
  • FIGURE 14.27: Convertible CAR Parts
  • FIGURE 14.28: Universal Donor Cells

INDEX OF TABLES

  • TABLE 2.1: Potential CAR-T Targeted Antigens Present on Hematological Malignancies
  • TABLE 2.2: Key Differences between the available Vectors
  • TABLE 2.3: The Seven CAR-T Therapies Available in the Market: A Brief Overview
  • TABLE 2.3: (CONTINUED)
  • TABLE 2.3: (CONTINUED)
  • TABLE 2.4: Toxicities Associated with CAR-T Treatment
  • TABLE 2.5: Strategies for the Future of CAR-T Therapies
  • TABLE 2.6: A Short List of ongoing CAR-T Studies on Solid Tumors
  • TABLE 2.7: New Target Antigens and New Target Cancers
  • TABLE 2.8: A Non-Comprehensive List of Allogeneic CAR-T Companies
  • TABLE 3.1: History of Development of CAR-T Cell Therapy
  • TABLE 3.2: Approved CAR-T Products, their Developers and Indications
  • TABLE 3.3: Other Promising CAR-T Product Candidates
  • TABLE 3.4: Increased CAR-T Activity
  • TABLE 3.5: Very Small Patient Population Addressed by CAR-T Therapy
  • TABLE 5.1: CAR-T Target Antigens on Hematalogical Malignancies
  • TABLE 5.2: CAR-T Target Antigens on Solid Tumors
  • TABLE 6.1: Top 20 Companies in CAR-T Patent Landscape
  • TABLE 6.2: Top 20 Research Centers in CAR-T Patent Landscape
  • TABLE 6.3: Top Twenty CAR-T Inventors
  • TABLE 6.4: Top Five CAR-T Patents with Most Family Members
  • TABLE 6.5: Top Five CAR-T Patents with Most Inventors in Co-Authorship
  • TABLE 6.6: Top Five Patents with Most Co-Applicants
  • TABLE 6.7: Top 5 CAR-T Patents with Most Co-Applicants
  • TABLE 7.1: Number of CAR-T Clinical Trials by Country
  • TABLE 7.2: Percent Target Distribution of CAR-T Clinical Trials
  • TABLE 7.3: CAR-T Targeted Biomarkers in the U.S. Clinical Trials
  • TABLE 7.4: CAR-T Targeted Biomarkers in Chinese Clinical Trials
  • TABLE 7.5: CAR-T Targeted Indications in the U.S. Clinical Trials
  • TABLE 7.6: CAR-T Targeted Indications in the U.S. Clinical Trials
  • TABLE 7.7: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
  • TABLE 7.7: (CONTINUED)
  • TABLE 7.8: CAR-T ClinicAl Trial Sponsor Companies & Institutions in China
  • TABLE 7.8: (CONTINUED)
  • TABLE 7.8: (CONTINUED)
  • TABLE 7.9: CAR-T Clinical Trial Sponsor Companies & Institutions in other Countries
  • TABLE 7.10: Clinical Trials of Fourth, Fifth and Gene Edited CAR-Ts
  • TABLE 7.10: (CONTINUED)
  • TABLE 7.10: (CONTINUED)
  • TABLE 7.10: (CONTINUED)
  • TABLE 7.10: (CONTINUED)
  • TABLE 8.1: A Short List of NIH Funding for CAR-T Research in 2022
  • TABLE 8.1: (CONTINUED)
  • TABLE 10.1: Hospital Reimbursement, Proposed & Final Rule FY 2022 and FY 2023
  • TABLE 10.2: List Prices of Kymriah and Yescarta in Europe
  • TABLE 10.3: Cost Components of Pre- and Post-CAR-T Cell Therapy, in E.U.
  • TABLE 10.4: Average Total Costs Pre- and Post CAR-T Cell Administration in E.U.
  • TABLE 10.5: Reimbursement for CAR-T Thrapies in France
  • TABLE 10.6: Reimbursement for CAR-T Therapies in Germany
  • TABLE 10.7: Reimbursement for CAR-T Therapies in Italy
  • TABLE 10.8: Reimbursement for CAR-T Therapies in Spain
  • TABLE 10.9: Reimbursement for CAR-T Therapies in U.K.
  • TABLE 11.1: Cost of Treating Blood Cancers
  • TABLE 12.1: Estimated Global Market for CAR-T Therapy by Product, 2021-2030
  • TABLE 12.2: Global Market for CAR-T by Geography, 2021-2030
  • TABLE 12.3: Global Market for CAR-T Therapies by Indication, 2021-2030
  • TABLE 14.1: Adicet's Broad Pipeline in Cancer
  • TABLE 14.2: AffyImmune's Affinity-Tuned Pipeline Products
  • TABLE 14.3: Alaunos' Advanced Platform Targeting Solid Tumors
  • TABLE 14.4: Aleta's CAR-T Engager Pipeline in High Unmet Need Indications
  • TABLE 14.5: Allogene's AlloCAR-T Pipeline
  • TABLE 14.6: Anixa's Product Pipeline
  • TABLE 14.7: Arbele's Product Pipeline
  • TABLE 14.8: Arcellx's Current Product Pipeline
  • TABLE 14.9: Artiva's NK Cell Therapy Pipeline for Cancer
  • TABLE 14.10: Atara's Robust Product Pipeline
  • TABLE 14.11: Autolus' Therapies in Development
  • TABLE 14.12: AvenCell's Clinical and Preclinical Pipeline
  • TABLE 14.13: Beam's Product Pipeline
  • TABLE 14.14: Bellicum's Pipeline of Investigational Immunotherapies
  • TABLE 14.15: Biosceptre's Product Pipeline
  • TABLE 14.16: Cabaletta's Autoimmune Therapy Candidates in Development
  • TABLE 14.17: Carina Biotech's Clinical Programs
  • TABLE 14.18: CARsgen's Product Pipeline
  • TABLE 14.21: Celyad's Diversified Pipeline
  • TABLE 14.22: Century's Pipeline Overview
  • TABLE 14.23: CRISPR Therapeutics' Immuno-Oncology Programs
  • TABLE 14.24: CytoSeek's Pipeline Product Candidates
  • TABLE 14.25: Cytovia's Product Pipeline
  • TABLE 14.26: Elicera's Product Portfolio
  • TABLE 14.27: Eureka's Product Pipeline
  • TABLE 14.28: EXUMA's Pipeline Assets
  • TABLE 14.29: Fate's Product Pipeline
  • TABLE 14.30: Gilead's Ongoing CAR-T Programs
  • TABLE 14.31: Gracell's Clinical Pipeline
  • TABLE 14.32: IASO's Diverse Product Pipeline
  • TABLE 14.33: iCell Gene's Product Pipeline
  • TABLE 14.34: ImmPACT Bio's Product Pipeline
  • TABLE 14.35: Inceptor's Diversified Cell Therapy Programs
  • TABLE 14.36: JW Therapeutics' Product Pipeline
  • TABLE 14.37: Kite's Pipeline Cancer Therapies
  • TABLE 14.38: Legend's Autologous Product Pipeline for Hematological Cancers
  • TABLE 14.39: Legend's Allogeneic Product Pipeline for Hematological & Solid Cancers
  • TABLE 14.40: Leucid's Product Pipeline
  • TABLE 14.41: Luminary's Product Pipeline
  • TABLE 14.42: Lyell's Diverse Pipeline Targeting Solid Tumor Cancers
  • TABLE 14.43: Minerva's Pipeline Products for Solid Tumors
  • TABLE 14.44: Mustang Bio's Five In Licensed CAR-T Programs
  • TABLE 14.45: NKarta's Product Pipeline
  • TABLE 14.46: Noile-Immune's PRIME-based Pipeline Products
  • TABLE 14.47: Oncternal's Product Pipeline
  • TABLE 14.48: oRNA's Pipeline Products
  • TABLE 14.49: Oxford Biomedica's CDMO Services Pipeline
  • TABLE 14.50: PeproMene's Product Pipeline
  • TABLE 14.51: Poseida's Allogeneic & Autologous Product Candidates
  • TABLE 14.52: Precigen's Pipeline
  • TABLE 14.53: Precision's CAR-T Immunotherapy Pipeline
  • TABLE 14.54: Quell's Pipeline
  • TABLE 14.55: SOTIO's Pipeline
  • TABLE 14.56: Tessa's Product Pipeline
  • TABLE 14.57: Tmunity's Product Pipeline
  • TABLE 14.58: Umoja's Product Pipeline
  • TABLE 14.59: Vor Biopharma's Product Pipeline against Blood Cancers
  • TABLE 14.60: Wugen's Product Pipeline
  • TABLE 14.61: Xenetic's Product Pipeline
  • TABLE 14.62: Xyphos' Product Pipeline
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!